52As regards, next, the argument that there is a genuine dispute, the outcome of which is uncertain, between the manufacturer of the originator medicine and a manufacturer of the generic version of that medicine who seeks to obtain access to the market for that medicine, the genuineness of their dispute, particularly when it is the subject of court proceedings, far from precluding the existence of any competition between them, rather constitutes evidence of the existence of a potential competitive relationship between them.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.